

# Corporate Action Notice



April 25, 2013

## Ratio Change and Stock Distribution Notice

### **Astellas Pharma Inc.**

DR CUSIP: 04623U102

DR ISIN: US04623U1025

DR Ticker Symbol: ALPMY

Ratio (DRs : Underlying Shares): 1:1

Please be advised that The Bank of New York Mellon, as Depositary, will change the ratio of the **Astellas Pharma Inc.**, Depositary Receipt ("DR") program from 1 DR representing 1 common share to 4 DRs representing 1 common share.

The ratio change will occur simultaneously with a 300% DSs distribution (or 3 additional DSs for each 1 DS held).

### **Please note the following:**

DR Record Date: May 9, 2013

DR Payable Date: May 10, 2013

DR Distribution Rate: 300% Distribution (or 3 additional DSs for each 1 DS held).

Old DR Ratio: 1 DR : 1 common share

**New DR Ratio: 4 DRs : 1 common share**

Effective date for DR ratio change: May 13, 2013

**Please note: A ratio change may impact the fees payable by ADR investors.**

Books will be closed from May 10, 2013 and will reopen on May 16, 2013 for Issuance and Cancellation transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

---

### ***New York***

Ravi Davis

Vice President

+1 212 815-4245

Ravi.davis@bnymellon.com

### ***London***

Damon Rowan

Vice President

+44 207 964 6527

damon.rowan@bnymellon.com

### ***Hong Kong***

Joe Oakenfold

Vice President

+852 2 840 9717

joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.